Doctors are not safe with some patients.

Published Date: 16 Feb 2023

Many physicians have encountered one or more serious or potentially dangerous patients over the years, and according to Medscape research, patient trust has declined.

Read Full News

Latest News

Will a Smart Toilet Turn the Home Into a Diagnostic Center?

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer Sues Johnson & Johnson Over Claim That Prostate Cancer Drug Cuts Risk Of Death

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

Doc Murdered 8 Patients? RFK Jr. Will 'Cost Lives'; $412M in Penile Injection Case

Health news and commentary gathered by MedPage Today staff

FDA Approves Novel Treatment for UTIs

New oral antibiotic gets a nod for uncomplicated urinary tract infections

Mission Health Urologists Disappear.

Following the takeover by HCA, experts identify the most recent departures.

More then ever, the healthcare industry needs qualified expert witnesses.

It can offer a fresh challenge as well as be the appropriate course of action in certain situations.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Latest News

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

Health news and commentary gathered by MedPage Today staff

New oral antibiotic gets a nod for uncomplicated urinary tract infections

Following the takeover by HCA, experts identify the most recent departures.

It can offer a fresh challenge as well as be the appropriate course of action in certain situations.

News All Time

The new first-line standard for advanced bladder cancer was produced by a landmark trial.

When compared to chemotherapy, enfortumab vedotin-pembrolizumab doubles OS and PFS.

Should Patients With Advanced Prostate Cancer Get Off the Active Surveillance Train?

Clearly defined rules are needed.

Even in those with HIV, a single dose of antibiotics was able to cure early syphilis.

In a randomized trial, one dosage showed no worse results than a triple-dose regimen.

Removing Cancer Survivors From Oncologic Treatment.

A new approach to care is required.

Cabazitaxel Lower-Dose Schedule Is Viable for Elderly Patients With mCRPC.

Neutropenia of grade three or above, with a twelve-fold reduction in neutropenic consequences.

AR-Pathway Inhibitor Switch for mCRPC is Superseded by Radionuclide Therapy.

With 177Lu-PSMA-617, the time to radiographic progression was doubled.

An RCT Supports HIF-2a Inhibition in Advanced RCC.

Belzutifan outperforms everolimus in the event of immunotherapy-TKI failure.

CAR T-Cell Therapy for Renal Cell Carcinoma: "We're Not There Yet".

Possibility of standard of care following current therapies, but significant barriers still need to be overcome.

Finding New Routes to Improve Renal Cell Carcinoma Outcomes.

It is necessary to intervene at several stages of the cancer immunity cycle in order to build on recent successes.

In severe cases of renal cell carcinoma, tyrosine kinase inhibitor activity is present.

Reactions to the "special medication" zanzalintinib in patients exposed and not exposed to cabozantinib.

Dietary inflammation is associated with the development of urologic cancers.

In health research, the relationship between dietary habits and cancer risks is still a major focus. The has been the subject of a recent meta-analysis.

In infants, laparoscopic robotic pyeloplasty is safe and has a success rate comparable to open surgery.

The results of minimally invasive pyeloplasty (MIP) for the primary cause, ureteropelvic junction obstruction (UPJO), were examined in a recent study.

Medical Bulletin November 30, 2023.

The top medical stories of the day are as follows: ADHD increases the risk of car crashes in older adults. ADHD is a neurodevelopmental disorder that is chronic and has symptoms.

Wellness Bulletin 25/November/2023.

Here are the top health stories for the day:Doctors performing 'Two Finger Test' will be guilty of misconductReiterating the fact that the Supreme.

The only viable solution for stress urinary incontinence with mesh slings is informed decision-making.

UK: A recent study thoroughly examined the short- and long-term mesh sling complications reported in European Urology Focus.

Black people who consume a few servings of whole grains have been shown to experience a slower rate of memory loss.

A slower rate of memory loss may be experienced by Black individuals who consume more whole grain-containing foods, such as popcorn, quinoa, and some breads and cereals.

Recommended News For You

Is Chemotherapy via Peripheral IV Access More Effective Than Central Lines for Testicular Cancer?

Alcohol Causes Cancer. We Should Be Drinking Less.

Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

According to new studies, some cancer patients can safely forego radiation therapy.

Pancreatic Cancer: A Novel CD40 Agonist-Chemo Combo Shows Promise.

In cases of metastatic or recurrent head and neck cancer, gene-guided immunotherapy falls short.

Recommended Articles For You

A Visual Journey Through Penile Cancer: Examining the Impact of Photos 

A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies  

Hemophilia: Pathophysiology, Genetics, and Treatment Advances 

Exploring the Mysteries of Myxoma: A New Frontier in Medical Research 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.

2.

Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects

3.

Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.

4.

An Eye Surgeon's Unexpected Discovery of the "Before and After".

5.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

1.

The Silent Signs: Uncovering Stomach Cancer Symptoms Before It's Too Late

2.

Anemia in Older Adults: Causes, Clinical Impact, and Evidence-Based Management

3.

Unlocking the Secrets of Hemoglobin: Exploring the Wonders of Life-Sustaining Iron Compounds

4.

Uncovering the Mystery of Burkitt's Lymphoma: A New Hope for Treatment

5.

Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI

2.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

4.

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

5.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot